JP2009507492A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507492A5
JP2009507492A5 JP2008530030A JP2008530030A JP2009507492A5 JP 2009507492 A5 JP2009507492 A5 JP 2009507492A5 JP 2008530030 A JP2008530030 A JP 2008530030A JP 2008530030 A JP2008530030 A JP 2008530030A JP 2009507492 A5 JP2009507492 A5 JP 2009507492A5
Authority
JP
Japan
Prior art keywords
gene
androgen
family member
group
comprises detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008530030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507492A (ja
JP5512125B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/035507 external-priority patent/WO2007033187A2/en
Publication of JP2009507492A publication Critical patent/JP2009507492A/ja
Publication of JP2009507492A5 publication Critical patent/JP2009507492A5/ja
Application granted granted Critical
Publication of JP5512125B2 publication Critical patent/JP5512125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008530030A 2005-09-12 2006-09-12 前立腺癌における再発性遺伝子融合 Active JP5512125B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US71643605P 2005-09-12 2005-09-12
US60/716,436 2005-09-12
US73035805P 2005-10-27 2005-10-27
US60/730,358 2005-10-27
US77904106P 2006-03-03 2006-03-03
US60/779,041 2006-03-03
US79559006P 2006-04-28 2006-04-28
US60/795,590 2006-04-28
PCT/US2006/035507 WO2007033187A2 (en) 2005-09-12 2006-09-12 Recurrent gene fusions in prostate cancer

Publications (3)

Publication Number Publication Date
JP2009507492A JP2009507492A (ja) 2009-02-26
JP2009507492A5 true JP2009507492A5 (OSRAM) 2009-08-27
JP5512125B2 JP5512125B2 (ja) 2014-06-04

Family

ID=37865521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008530030A Active JP5512125B2 (ja) 2005-09-12 2006-09-12 前立腺癌における再発性遺伝子融合

Country Status (8)

Country Link
US (9) US7718369B2 (OSRAM)
EP (2) EP2612870A1 (OSRAM)
JP (1) JP5512125B2 (OSRAM)
AU (1) AU2006291054B2 (OSRAM)
CA (2) CA2622295C (OSRAM)
DE (1) DE06814528T1 (OSRAM)
IL (1) IL190095A (OSRAM)
WO (1) WO2007033187A2 (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008012B2 (en) * 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2612870A1 (en) 2005-09-12 2013-07-10 The Regents of the University of Michigan Recurrent gene fusions in prostate cancer
US8273539B2 (en) * 2006-09-25 2012-09-25 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
CA3018520C (en) 2006-10-10 2022-05-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2010508855A (ja) * 2006-11-08 2010-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌マーカーとしてのspink1およびその使用
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
CA2692441C (en) * 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
AU2008275303B2 (en) 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
CA2693973A1 (en) * 2007-07-18 2009-01-22 Gen-Probe Incorporated Compositions and methods to detect tmprss2/erg transcript variants in prostate cancer
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
WO2009135019A2 (en) * 2008-05-01 2009-11-05 Beth Israel Deaconess Medical Center Methods and compositions for prostate cancer immunotherapy
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9458213B2 (en) 2009-02-19 2016-10-04 Cornell University Compositions and methods for diagnosing prostate cancer based on detection of SLC45A3-ELK4 fusion transcript
US8143232B2 (en) * 2009-03-03 2012-03-27 The Regents Of The University Of Michigan Gene fusion targeted therapy
US8765916B2 (en) * 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US8426133B2 (en) 2009-05-26 2013-04-23 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulation by intragenic differential expression
CN102712953A (zh) * 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
JP2013520419A (ja) * 2010-02-19 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 遺伝子融合を標的とする治療
SG10201505769PA (en) * 2010-07-27 2015-09-29 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012075069A2 (en) * 2010-12-02 2012-06-07 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
EP2678446B1 (en) * 2011-02-24 2017-06-28 Ventana Medical Systems, Inc. Presence of erg gene rearrangements and protein over-expression in low grade pin (lg-pin) in prostate biopsies
CA2833534A1 (en) 2011-04-18 2012-10-26 Cornell University Molecular subtyping, prognosis and treatment of prostate cancer
CN103874706B (zh) * 2011-04-28 2016-06-08 贝勒医学院 在人类前列腺癌富集的作为生物标记物的再生嵌合rna
WO2013022974A1 (en) * 2011-08-08 2013-02-14 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Isolation and detection of cancer cells
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
BR112014013544A8 (pt) 2011-12-30 2017-06-13 Abbott Molecular Inc materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata
SG10201605210PA (en) 2012-01-31 2016-08-30 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
JP6044935B2 (ja) 2013-03-11 2016-12-14 学校法人日本大学 新規piポリアミド
US20160000946A1 (en) * 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
US9890425B2 (en) 2013-03-15 2018-02-13 Abbott Molecular Inc. Systems and methods for detection of genomic copy number changes
EP3121291A4 (en) * 2014-03-20 2017-08-30 Konica Minolta, Inc. Probe reagent and fish using probe reagent
CN103923925B (zh) * 2014-05-07 2016-06-08 杨举伦 抑制ER81基因表达的siRNA及其在乳腺癌细胞中的应用
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
JP6920683B2 (ja) 2015-10-08 2021-08-18 凸版印刷株式会社 ピロールイミダゾール含有ポリアミドを用いた標的二本鎖核酸分子の濃縮方法およびキット
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018175273A1 (en) * 2017-03-21 2018-09-27 The Regents Of The University Of Michigan Erg targeted therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CA3072061A1 (en) 2017-08-04 2019-02-07 The Regents Of The University Of Michigan Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US11741686B2 (en) 2020-12-01 2023-08-29 Raytheon Company System and method for processing facility image data
CN112522404B (zh) * 2020-12-10 2023-06-09 珠海中科先进技术研究院有限公司 一种用于检测前列腺癌的多重荧光pcr试剂盒
CN113025721A (zh) * 2021-04-28 2021-06-25 苏州宏元生物科技有限公司 一种前列腺癌诊断和预后评估试剂盒
CN115083516B (zh) * 2022-07-13 2023-03-21 北京先声医学检验实验室有限公司 一种基于靶向RNA测序技术检测基因融合的Panel设计和评估方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4839296A (en) 1985-10-18 1989-06-13 Chem-Elec, Inc. Blood plasma test method
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4853219A (en) * 1987-08-06 1989-08-01 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
EP0731175A3 (en) 1989-07-11 2004-05-26 Gen-Probe Incorporated Oligonucleotide probes for HIV nucleic acid
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
EP1362913B1 (en) 1992-10-30 2006-01-25 The General Hospital Corporation Interaction trap system for isolating proteins
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
CA2156288C (en) 1993-02-19 2005-10-18 Junichi Yano Glycerol derivative, device and pharmaceutical composition
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP3448090B2 (ja) 1994-02-16 2003-09-16 浜松ホトニクス株式会社 エネルギー移動検出法およびその装置
US20050214309A1 (en) 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
EP0787200B1 (en) 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5856125A (en) * 1995-06-05 1999-01-05 The United States Of America As Represented By The Department Of Health And Human Services ETS2 repressor factor (ERF) genetic locus and its products
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
KR19990087802A (ko) 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
CA2252048C (en) 1996-04-12 2008-03-11 The Public Health Research Institute Of The City Of New York, Inc. Detection probes, kits and assays
EP0929814A1 (en) 1996-10-07 1999-07-21 Meat And Livestock Commission Assay for duroc muscle fibre type
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US6943236B2 (en) * 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020119531A1 (en) 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US20030103981A1 (en) 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US6043033A (en) 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US6198107B1 (en) 1997-03-07 2001-03-06 Clare Chemical Research, Inc. Fluorometric detection using visible light
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP0998565A1 (en) 1997-07-11 2000-05-10 Introgene B.V. Interleukin-3 gene therapy for cancer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
ATE490977T1 (de) 1998-06-01 2010-12-15 Agensys Inc Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
AU4563599A (en) 1998-06-16 2000-01-05 Regents Of The University Of California, The Exons 4 and 7 encode separate transactivating and chromatin localizing domains in esx
US6166194A (en) 1998-06-29 2000-12-26 Myriad Genetics, Inc. TMPRSS2 is a tumor suppressor
DE69941333D1 (de) 1998-07-02 2009-10-08 Gen Probe Inc Molekulare fackeln
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
AU748523B2 (en) 1998-08-14 2002-06-06 Aventis Pharmaceuticals Inc. Adenovirus formulations for gene therapy
CN1257286C (zh) 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
ES2317704T3 (es) 1998-09-02 2009-04-16 Diadexus, Inc. Un nuevo metodo para el diagnostico, seguimiento, estadificacion. imagineria y tratamiento de distintos canceres.
EP1117836A2 (en) 1998-09-30 2001-07-25 Millennium Pharmaceuticals, Inc. Expressionanalysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6872811B1 (en) 1998-09-30 2005-03-29 Millennium Pharmaceuticals, Inc. HRPCa9 and HRPCa10 nucleic acids and polypeptides
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527758A (ja) 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
WO2000065067A2 (en) 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
EP1179093A1 (en) 1999-05-14 2002-02-13 Chiron Corporation Expression of ets-domain proteins in cancer
EP1055734B1 (en) 1999-05-24 2004-10-13 Tosoh Corporation Method for assaying ribonucleic acid
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
DE10004102A1 (de) 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001088124A2 (en) 2000-05-16 2001-11-22 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of erg
US7060436B2 (en) 2000-06-17 2006-06-13 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
JP2004504068A (ja) 2000-07-27 2004-02-12 ザ オーストラリアン ナショナル ユニバーシティー コンビナトリアル・プローブ及びそのための用途
JP2004509882A (ja) 2000-09-21 2004-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Rafキナーゼ阻害剤としてのイミダゾール誘導体
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20040009481A1 (en) 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
EP1409727B1 (de) 2001-09-06 2005-11-09 Adnagen AG Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
EP1474433A4 (en) 2002-02-20 2005-02-23 Sirna Therapeutics Inc VALIDATION AND IDENTIFICATION OF RNA INTERFERENCE FACILITATED TARGETS USING SHORT INTERFERENT NUCLEIC ACID (siNA)
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004092397A2 (en) 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
US8679789B2 (en) 2003-05-01 2014-03-25 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1636379A2 (en) 2003-06-26 2006-03-22 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
ATE451477T1 (de) 2003-09-05 2009-12-15 Univ Jefferson Diagnose und überwachung von hepatozellulärem karzinom
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
WO2005042732A2 (en) * 2003-10-28 2005-05-12 Wisconsin Alumni Research Foundation STABLE CELL LINES EXPRESSING HERG1a AND HERG1b
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
EP2383350B1 (en) 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
JP2008509673A (ja) 2004-08-13 2008-04-03 ミレニアム ファーマシューティカルズ, インコーポレイテッド ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
AU2005280162B2 (en) 2004-08-27 2012-04-26 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7638278B2 (en) 2005-05-13 2009-12-29 The Board Of Trustees Of The Leland Stanford Junior University Markers of DNA copy number alteration for improved prognostication in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2612870A1 (en) 2005-09-12 2013-07-10 The Regents of the University of Michigan Recurrent gene fusions in prostate cancer
CA3018520C (en) 2006-10-10 2022-05-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
CA2692441C (en) 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
WO2009044899A1 (ja) 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
US9458213B2 (en) 2009-02-19 2016-10-04 Cornell University Compositions and methods for diagnosing prostate cancer based on detection of SLC45A3-ELK4 fusion transcript
US8765916B2 (en) * 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
CN102712953A (zh) 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物

Similar Documents

Publication Publication Date Title
JP2009507492A5 (OSRAM)
DE06814528T1 (de) Wiederkehrende genfusionen bei prostatakrebs
EP3018216B1 (en) Recurrent gene fusions in prostate cancer
JP2017108751A5 (OSRAM)
AU784861B2 (en) Gene expression profiling of inflammatory bowel disease
JP2010532663A5 (OSRAM)
US20110082188A1 (en) Gene expression profiling of inflammatory bowel disease
JP6531312B2 (ja) Bcr−abl阻害剤耐性関連変異の検出方法及びこれを用いたbcr−abl阻害剤耐性を予測するためのデータ取得方法
WO2013141266A1 (ja) 新規ret融合体の検出法
JP2004528810A5 (OSRAM)
JP2005537007A5 (OSRAM)
JP2008512984A5 (OSRAM)
US20120039887A1 (en) Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript
US10167517B2 (en) MIPOL1-ETV1 gene rearrangements
Esten Nakken et al. Multiple inflammatory-, tissue remodelling-and fibrosis genes are differentially transcribed in the livers of Abcb4 (−/−) mice harbouring chronic cholangitis
Debrus et al. The zinc finger-only protein Zfp260 is a novel cardiac regulator and a nuclear effector of α1-adrenergic signaling
KR100947738B1 (ko) 피부 노화 진단 키트 및 피부 노화 진단 방법
BRPI0610794A2 (pt) métodos para diagnosticar uma susceptibilidade a um cáncer e para predizer um risco aumentado de cáncer, kit para ensaiar uma amostra de um indivìduo para detectar uma susceptibilidade a um cáncer, e, métodos para diagnosticar um risco aumentado de cáncer e para diagnosticar um cáncer associado com chr8q24.21
CN109988830A (zh) 一种用于脓毒症标志物的lncRNA及其应用
KR100976005B1 (ko) 만성 류마티스관절염 질환 감수성 유전자, 이의 단백질,이들을 이용한 만성 류마티스관절염의 발증가능성의 판정방법 및 판정 키트, 및 만성 류마티스관절염의 치료 방법및 치료 약제
CN110195104A (zh) 一种预测缺血性心肌病的分子标志物
WO2003048767B1 (en) Use of elavl-1 gene in the detection and modulation of apoptosis
JP2011518541A5 (OSRAM)
JP4444576B2 (ja) 2型糖尿病関連遺伝子
JP4348456B2 (ja) グルココルチコイド製剤への感受性の遺伝子診断に用いることができる変異型ポリヌクレオチドおよび核酸分子